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1  |  INTRODUC TION
Anti- Müllerian hormone (AMH), also known as Müllerian inhibiting 
substance, is a member of the transforming growth factor- β family. 
AMH is secreted by Sertoli cells of male fetuses and induces regres-
sion of Müllerian ducts during male differentiation.1 After birth, its 
regulatory role in sex differentiation is lost and AMH begins to be 
produced by granulosa cells of preantral and small antral follicles in 
the ovaries.2 Serum AMH concentration is an excellent candidate 
marker of ovarian reserve because AMH is secreted from all devel-
oping follicles, and both serum AMH levels and number of antral fol-
licles decline with age.
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Abstract
Background: We established age- group- specific reference intervals for serum anti- 
Müllerian hormone (AMH) levels in a Korean population and investigated the effec-
tiveness of AMH assay for polycystic ovary syndrome (PCOS) diagnosis.
Methods: We analyzed serum levels of AMH, follicle- stimulating hormone (FSH), and 
luteinizing hormone (LH) from 1540 Korean women. Subjects were divided into three 
groups: healthy, benign gynecologic diseases, and PCOS. Age- group- specific refer-
ence intervals and AMH diagnostic performance were estimated.
Results: The	PCOS	group	had	 a	median	AMH	 level	 of	 7.0	µg/L,	which	was	higher	
than	for	the	healthy	(1.8	µg/L)	and	the	benign	gynecologic	diseases	(2.7	µg/L)	groups.	
The	upper	97.5%	reference	limits	for	age	groups	12–	20	years,	21–	34	years,	and	35–	
46	 years	 were	 13.2	 µg/L,	 15.8	 µg/L,	 and	 6.6	 µg/L,	 respectively.	 The	 area	 under	
the curve (AUC) values to estimate AMH ability to discriminate PCOS from healthy 
women	for	each	age	group	were	0.741,	0.785,	and	0.789,	respectively.	AUCs	for	LH/
FSH	were	0.719,	0.672,	and	0.590.
Conclusions: The better diagnostic ability of AMH over LH/FSH in women of late 
childbearing ages indicates that age and other clinical characteristics should be con-
sidered when interpreting these test results.
K E Y W O R D S
age- group- specific, anti- Müllerian hormone, diagnostic performance, polycystic ovary 
syndrome, reference interval
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In addition to be as a marker for ovarian reserve in healthy 
women, serum AMH level can also serve as a marker for ovarian 
pathophysiology, including polycystic ovary syndrome (PCOS). 
PCOS is the most common cause of chronic anovulation and hyper-
androgenism in young women. Both result in substantial psycholog-
ical, economic, and social consequences.3 In women suffering from 
PCOS, increased AMH production per follicle, as well as higher num-
ber of preantral and small antral follicles, contribute to increased 
serum AMH levels.4 Moreover, a strong correlation has been ob-
served between ultrasonographic antral follicular counts (AFC) and 
serum AMH levels.5 Thus, serum AMH can be a surrogate for AFC as 
a diagnostic marker for PCOS.
However, it is questionable whether serum AMH alone can 
provide sufficient diagnostic value for PCOS. Serum AMH can be 
influenced by multiple factors. An association between obesity 
and significantly lower serum AMH has been reported, where 
AMH	 levels	 were	 34%–	65%	 lower	 in	 obese	 women	 compared	
with non- obese women.6,7 Furthermore, serum AMH is pre-
dominantly dependent on age. Various cutoff values for serum 
AMH have been proposed for discriminating PCOS women from 
healthy women.8 However, few studies have evaluated age- 
related or age- specific reference intervals of serum AMH, espe-
cially for data generated from automated assays.9–	12 Moreover, 
PCOS prevalence and characteristics of the control population 
would influence diagnostic performance in a real- world setting. 
Additionally, ethnicity, which is strongly associated with anthro-
pometric characteristics, risk for other benign gynecologic condi-
tions, and the age range of the subject population, can all affect 
determination of appropriate cutoff values and overall accuracy 
of an AMH test.
We aimed to establish age- group- specific reference intervals 
of serum AMH levels in a healthy Korean population. We also com-
pared the diagnostic performance of the AMH age- group- specific 
reference intervals estimated in this study to those from previous 
studies. Finally, we analyzed the diagnostic performance of serum 
AMH compared with the LH- to- FSH ratio (LH/FSH) to investigate 
the clinical utility of AMH when applied to various age groups and 
clinical settings.
2  |  MATERIAL S AND METHODS
2.1  |  Subject characteristics
Between	May	2017	and	January	2019,	serum	AMH,	luteinizing	hor-
mone (LH), follicle- stimulating hormone (FSH), and estradiol (E2) 
assays	were	simultaneously	 requested	for	1631	females,	ages	12–	
70	years,	 at	Severance	Hospital.	The	serum	samples	had	been	 re-
quested for hormonal assays on unspecified day of the menstrual 
cycle. Subjects’ medical records between 180 days before and 
90 days after laboratory test administration were requested and 
reviewed.	After	 excluding	patients	 aged	52–	70	 years	 and	patients	
diagnosed with any kind of cancers including ovarian carcinoma, or 
patients with premature ovarian failure and those who are pregnant 
or were pregnant until recently, 1540 subjects were included in the 
analyses.
Study subjects were divided into three groups: (i) apparently 
healthy women without any diagnosed gynecologic diseases, (ii) pa-
tients with benign gynecologic diseases or symptoms, and (iii) pa-
tients with PCOS. The subject groups were defined mainly based 
on the registered diagnosis by clinicians in medical records. PCOS 
diagnosis was made according to the Rotterdam Consensus, as 
previously described.13 Diagnosis of benign gynecologic diseases 
(Table S1) was made based on ultrasonography, laboratory test re-
sults, and clinical manifestations. Expert endocrinologists and gy-
necologists performed comprehensive evaluations and made final 
diagnoses for all study patients.
2.2  |  Assays
Serum samples were tested immediately upon arrival in the labora-
tory. AMH levels were measured by the Elecsys AMH assay utilizing 
electrochemiluminescence immunoassay principle with the cobas 
e 602 analyzer (Roche Diagnostics GmbH, Mannheim, Germany). 
Serum concentrations of LH, FSH, and E2 were assayed with the 
chemiluminescence- based UniCel™ DxI 800 Access Immunoassay 
System (Beckman Coulter Inc.,). All assay procedures were per-
formed following the manufacturers’ instructions.
2.3  |  Statistical methods
Statistical analyses were performed using Analyse- it Software 
v5.65 (Analyse- it Software Ltd,). Values are presented as means and 
standard	deviations	or	medians	and	1st	to	3rd	quartiles.	The	Steel–	
Dwass–	Critchlow–	Fligner	test	was	conducted	to	detect	differences	
between the medians of all pairs of groups to compensate for alpha 
errors from multiple comparisons. Age- group- specific reference in-
tervals were calculated using a bootstrapped nonparametric method 
for	95%	central	distribution	(2.5–	97.5	percentiles).	Receiver	operat-
ing characteristic (ROC) curve analysis was performed to evaluate 
the diagnostic parameter performance, including serum AMH level. 
Youden's index was calculated to determine the optimal cutoff value 
of serum AMH for each age group. p- Values less than 0.05 were con-
sidered significant.
2.4  |  Ethical approval
This study protocol was reviewed and approved by the Institutional 
Review Board of Gangnam Severance Hospital in Seoul, Korea (No. 
3-	2020-	0367).	As	this	study	is	a	retrospective	cross-	sectional	case-	
control study only utilizing medical records that does not include the 
patients’ personal information, informed consents were waived by 
the IRB.
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3  |  RESULTS
3.1  |  Patient characteristics
Among	the	1540	subjects,	347	(22.5%)	were	assigned	to	the	healthy	
group,	753	(48.9%)	to	the	benign	diseases	group,	and	440	(28.6%)	
to the PCOS group. Age, body mass index (BMI), and measured hor-
mone levels are summarized for each group in Table 1. BMI in the 
PCOS group was significantly higher compared with the healthy 
population (p = 0.0025) and was insignificantly higher than the be-
nign diseases group. AMH, FSH, LH, and LH/FSH levels were all sig-
nificantly higher in the PCOS group than in the healthy or benign 
diseases groups (p < 0.0001 for all comparisons). Also, AMH levels 
were higher in the benign diseases group than the healthy group 
(p = 0.0063).
3.2  |  Establishment of AMH reference intervals
The healthy population was defined as the reference group 
here.	 The	 reference	 intervals	 were	 set	 as	 nonparametric	 2.5–	
97.5	 percentiles.	 The	 reference	 intervals	 along	 with	 the	 mean,	
median, and upper 95 percentile reference limits of AMH are 
presented	 for	 each	 age	 group	 in	Table	2.	Upper	97.5	percentile	
limits	of	reference	intervals	for	the	12–	20,	21–	34,	and	35–	46	age	
groups were 13.2, 15.8, and 6.6, respectively. These age group 
values were employed in subsequent analyses of diagnostic 
performance.
3.3  |  Diagnostic performance of AMH for PCOS 
with different age- related reference intervals
We compared the diagnostic utility of the reference intervals cal-
culated in this study to those of various age- specific or age- related 
reference limits suggested by recent studies9,10 or the assay manu-
facturer. Age- specific or age- related reference limits (Table S2) 
were applied to each age or age group to estimate overall diag-
nostic performance characteristics (Table 3). We calculated the 
sensitivity, specificity, positive predictive value (PPV), and nega-
tive predictive value (NPV) for each set of reference limits. The 
set of age- specific reference limits presented by Evliyaoglu et al10 
showed relatively high sensitivity of 0.663 and had a Youden's 
index of 0.430.





diseases (n = 753) p- Valueb  PCOS (n = 440) p- Valuec  p- Valued 
Mean age (years) 32.5 ± 8.9 31.1 ± 9.0 0.0758 26.2 ± 6.3 <0.0001 <0.0001
BMI (kg/m2) 21.2	(18.9–	23.8) 21.5	(19.3–	25.0) 0.2215 22.4	(19.7–	26.3) 0.0025 0.0520
AMH (μg/L) 1.8	(0.4–	4.4) 2.7	(0.7–	5.3) 0.0063 7.0	(4.4–	10.4) <0.0001 <0.0001
Estradiol (ng/L) 51.0	(31.0–	99.0) 49.0	(28.0–	80.0) 0.7344 50.5	(34.0–	76.6) 0.3431 0.7042
FSH (IU/L) 7.1	(5.1–	10.5) 7.2	(5.4–	9.6) 0.9306 6.4	(5.3–	7.7) <0.0001 0.0001
LH (IU/L) 5.8	(3.2–	10.6) 5.5	(3.3–	10.7) 0.9399 8.7	(4.7–	14.0) <0.0001 <0.0001
LH/FSH 0.72	(0.41–	1.24) 0.68	(0.43–	1.18) 0.9629 1.39	(0.75–	2.12) <0.0001 <0.0001
Note: Data are shown as means ± standard deviations or medians (1st to 3rd quartiles).
Abbreviations: AMH, anti- Müllerian hormone; BMI, body mass index; FSH, follicle- stimulating hormone; LH, luteinizing hormone; PCOS, polycystic 
ovary syndrome.
aApparently healthy women without any diagnosed gynecologic diseases.
bHealthy population versus benign gynecologic diseases.
cHealthy population versus PCOS.
dBenign gynecologic diseases versus PCOS.
TA B L E  2 Age-	group-	specific	reference	limits




Median (1st to 3rd 
quartiles)
2.5 percentile reference 
limit (90% CI)





12–	20	(42) 3.8 ± 3.9 2.8	(0.0–	5.7) 0.01	(0.01–	0.01) 13.2	(10.5–	14.2) 11.8	(9.6–	14.2)
21–	34	(161) 4.2 ± 3.8 3.5	(1.5–	5.6) 0.02	(0.01–	0.06) 15.8	(12.5–	18.3) 12.4	(10.6–	15.4)
35–	46	(126) 1.5 ± 1.8 1.0	(0.2–	2.1) 0.01	(0.01–	0.01) 6.6	(5.2–	9.2) 5.3	(4.5–	6.7)
Abbreviations: AMH, anti- Müllerian hormone; CI, confidence interval; SD, standard deviation.
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3.4  |  Determination of AMH cutoff values
We conducted ROC analysis to obtain optimal cutoff values for each 
age group with better discriminative power than the reference lim-
its. The healthy and benign diseases groups were used as control 
groups individually and collectively. Areas under curve (AUC), cutoff 
values, Youden's indexes, and diagnostic performance parameters 
for all age groups and control groups are summarized in Table 4. The 
AUC values compared with the healthy group as the control were 
0.741,	0.785,	 and	0.789	 for	 age	groups	of	12–	20,	21–	34,	 and	35–	
46 years old, respectively. When the benign disease group was used 
as	the	control,	the	AUC	values	were	0.679,	0.719,	and	0.778	for	the	
same age groups.
3.5  |  Comparison of LH/FSH and AMH diagnostic 
performance for PCOS
In	 the	 initial	 ROC	 analysis	 for	 all	 subjects,	 ages	 12–	51	 years	
(N	 =	1540),	 the	AUC	values	 (and	95%	confidence	 intervals	 and	p- 
values)	for	AMH,	E2,	LH,	FSH,	and	LH/FSH	were	0.798	(0.775–	0.821,	
p	<	0.0001),	0.505	(0.474–	0.535,	p	=	0.7667),	0.604	(0.574–	0.633,	
p	 <	 0.0001),	 0.597	 (0.569–	0.625,	p	 <	 0.0001),	 and	 0.706	 (0.678–	
0.734,	p < 0.0001), respectively. The AUC value for E2 was too low 
to be a diagnostic marker for PCOS, but LH/FSH yielded a signifi-
cantly higher AUC than LH or FSH alone (p < 0.0001). ROC curves 
for LH/FSH and AMH according to age group and control type are 
depicted in Figure 1.
4  |  DISCUSSION
In this study, we established age- group- specific reference in-
tervals of serum AMH levels in Korean women, and we also es-
timated the diagnostic utility of AMH for PCOS by applying the 
aforementioned reference intervals and other possible cutoffs 
calculated from our data. Both serum AMH levels and the number 
of antral follicles decline with age in healthy ovulatory women.14 
Furthermore, this age- based decline in AMH levels is also known 
to be much less pronounced in PCOS women.15,16 Therefore, it 
could be more appropriate to use multiple age- related cutoff 
values instead of a universal cutoff as a diagnostic threshold. 
Previous studies have reported that age- specific reference limits 
or multiples of the median (MoM) can significantly increase the 
diagnostic utility of AMH.9,10
Evliyaoglu et al10 analyzed serum AMH levels together with 
other	hormones	in	4712	reproductive-	aged	women	including	1132	
PCOS patients and 525 primary ovarian insufficiency (POI) patients. 
The authors presented AMH reference limits for each age ranging 
14–	50	years.	Their	age-	specific	AMH	reference	limits	showed	high	
discriminatory power for PCOS diagnosis in patients over 18 years 
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Chinese	women	20–	44	years	old.	 The	 reference	 intervals	 derived	
from healthy women were subsequently applied to a separate co-
hort	of	751	women	including	473	PCOS	patients.	The	MoM	for	AMH	
in PCOS women was consistently higher than those for controls 
across all ages. The difference was particularly prominent in women 
aged	36–	40	years.
In this context, we examined the clinical utility of AMH level with 
age- related reference limits in Korean women. In this study, the AUC 
value	 for	AMH	calculated	 from	all	 subjects	aged	12–	51	years	was	
0.798,	 which	 is	 similar	 to	 results	 from	 several	 previous	 studies.17 
However, the reference interval for each age group in our study was 
notably higher than that from Evliyaoglu et al.10 There are several 
possible explanations for this discrepancy. First, racial/ethnic dif-
ferences between the study populations could affect AMH levels, 
that is, genetic and environmental factors could cause the disparity 
between racial and ethnic groups.18 For example, the median BMI 
for our reference group was 21.2, while that of a previous study was 
26.1.10 The relatively low BMI in our subjects might result in higher 
serum AMH reference limits. In some previous studies, obesity was 
reported to be related to lower serum AMH levels.6,7 Previous stud-
ies from Asia reported AMH reference intervals and median BMIs 
similar to those in this study.11,19 Differences between the assay 
methods used in the studies and how reference groups were defined 
may also have affected the different AMH levels.
F I G U R E  1 Receiver	operating	characteristics	curves	of	anti-	Müllerian	hormone	(AMH)	and	the	luteinizing	hormone	to	follicle-	stimulating	
hormone ratio (LH/FSH) according to age groups and control types
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Meanwhile, the diagnostic performance of AMH for PCOS with 
age- group- specific reference limits was not entirely satisfactory. 
Additionally, the age- specific reference limits reported in previous 
studies9,10 and the age- group- specific reference limits suggested 
by the assay manufacturer also only offered limited performance 
for our study population (Table 3). This may be due to overlaps in 
the distribution of AMH concentrations from healthy women and 
PCOS patients in the Korean sample population. Racial and ethnic 
differences could affect the degree of overlapping in AMH concen-
tration distributions between healthy women and PCOS patients. 
Consequently, we tried a more elaborate approach to determine op-
timal AMH cutoff levels for PCOS diagnosis.
In ROC analysis, AUC values were consistently higher in older 
age groups regardless of control type. This was consistent with pre-
vious studies that reported a more modest decline of AMH levels 
with age in PCOS women than in healthy women.20,21 Interestingly, 
the sensitivity was lower, but the specificity was higher at the opti-
mal cutoff point in the older age group (Table 4), whereas the sensi-
tivity	at	fixed	95%	specificity	was	higher	in	the	older	age	group.	This	
means that gain of specificity outweighed loss of sensitivity along 
with increasing cutoff values in the older age group. Additionally, the 
higher AUC value and smaller variability between the cutoff values 
determined	 by	 95%	 sensitivity,	maximum	Youden	 index,	 and	 95%	
specificity were noticeable in the older age group. This would mean 
that inter- individual variation in AMH levels is smaller in older age 
groups, particularly among healthy women.
We also calculated AUC values according to age group and con-
trol type including healthy women and patients with benign gyneco-
logic diseases. For all age groups, the AUC values were higher when 
the healthy group alone was used as a control than when the benign 
diseases group alone or both were applied as a control (Figure 1). 
This means that careful consideration is needed to assess the actual 
utility of AMH in routine clinical diagnostic application. Given the 
context surrounding AMH testing, patients may be suffering from 
other gynecologic conditions, including anovulation, if not PCOS.22 
Including only normal cycling women in a control group could re-
sult in an overestimation of the diagnostic performance of AMH for 
PCOS.
Meanwhile, the AMH AUC values were significantly higher than 
those	of	LH/FSH,	except	 for	 the	12–	20	year	age	group	 (Figure	1).	
Other potential biomarkers for PCOS diagnosis include LH/
FSH.13,23,24 The diagnostic performance of biomarkers would de-
pend on several characteristics of the subject population.25 Our re-
sults show that the age group of a patient is one of the key aspects 
to consider when selecting an appropriate biomarker for efficient 
PCOS diagnosis and for interpreting results.
Numerous recent articles have focused on several parameters 
that can affect the association between AMH and PCOS. It was 
reported	 that	 8.2%–	46.0%	 of	 PCOS	 patients	 had	 metabolic	 syn-
drome.26,27 A significant negative correlation between serum AMH 
and insulin resistance had been observed in PCOS women.28,29 
Abdolhian et al30 showed that an exercise intervention can signifi-
cantly decrease AMH levels. AMH levels in PCOS cases could be 
regulated by a complicated mechanism, because PCOS is a complex 
reproductive and hormonal disorder that can derange metabolic pa-
rameters. Further research into the mechanism of AMH secretion 
control and its association with metabolic abnormalities in PCOS is 
necessary.
A major shortcoming of this study is that it was performed 
retrospectively. However, to minimize potential selection bias, 
we included all female patients who were requested to undergo a 
predefined set of hormonal assays conducted within the same day, 
regardless of their purpose of visit or reason for admission. The sec-
ond limitation is that the subject groups were classified mainly based 
on the registered diagnosis in medical records. The clinical/labora-
tory/ultrasonographic evidences for PCOS patients were hard to 
be retrieved at once. To make up for this, we additionally examined 
medical histories for a portion of PCOS patients to estimate the dis-
tribution of different phenotypes of PCOS in the present study. Of 
the	48	sample	PCOS	patients,	27	(56.3%)	were	phenotype	A	[hyper-
androgenism (HA) + ovulatory dysfunction (OD) + polycystic ovaries 
(PCO)],	 followed	by	10	(20.8%)	phenotype	B	 (HA	+	OD),	8	 (16.7%)	
phenotype	D	 (OD	+	PCO),	and	3	 (6.3%)	phenotype	C	 (HA	+	PCO)	
patients. Thirdly, there may have been missed evidences that was 
not sufficient to support a definite diagnosis, but nevertheless the 
implication of an underlying disease was present. For example, there 
might be significant amount of patients with isolated polycystic 
ovarian morphology, signs of hyperandrogenism, or un- ovulation, 
in control group. We could not estimate how much this proportion 
could be, since evidences of the three criteria were not be evalu-
ated directly by the authors. Moreover, this also could attribute to 
misclassification of PCOS patients into benign gynecologic diseases 
group. There might be cases of amenorrheic or irregular menstrua-
tion patients with pathologically high AFC, for whom the diagnosis 
of PCOS had yet not registered for some reasons. Those kinds of 
patients could have been missed through our study design.
A major strength of our study is that we further divided the con-
trol group into ostensibly healthy women and patients with benign 
gynecologic diseases, allowing us to obtain more relevant diagnos-
tic performance characteristics that reflect the clinical situation in 
which the serum AMH test would be applied. This study also has the 
advantage of its comparative estimation of AMH diagnostic perfor-
mance based on reference limits from the literature.
In conclusion, we established the reference intervals of serum 
AMH levels according to subject age groups and assessed their util-
ity for PCOS diagnosis. Serum AMH assay showed acceptable diag-
nostic performance for PCOS compared with LH/FSH, particularly 
in older women of childbearing age. To utilize the AMH test properly 
and interpret its result appropriately, a thorough consideration of 
patient age is required.
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